RxDoctor Payments Data

Anaita Panthaky

Acute Care · Loma Linda, CANPI 1508317843

Payments from drug & device makers

$4,018in general payments, 2019–2025

Across 137 payments — averaging $29.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$596
  • AOP Health US, LLC$488
  • Boehringer Ingelheim$347
  • Amgen$239
  • Edwards Lifesciences$238
  • Bayer$235
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$4,018100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,018 in reported general payments places this provider in the 90th percentile of 1,153 acute care providers in California.

See all acute care providers in California

Medicare billing

Part B allowed, 2024
$27,159
Medicare patients
163
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab53$59,853
EntrestoSacubitril/Valsartan28$33,981
XareltoRivaroxaban16$25,410
EliquisApixaban18$19,659
Clonidine28$6,321
Candesartan Cilexetil39$4,311
Rosuvastatin Calcium165$3,206
Atorvastatin Calcium157$1,656
Losartan Potassium123$1,346
Ranolazine ErRanolazine18$1,231
Isosorbide Mononitrate ErIsosorbide Mononitrate53$928
Irbesartan48$868
Amlodipine Besylate131$813
Ezetimibe44$645
Metoprolol Succinate48$616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$596$33,98128 claims
Johnson & JohnsonXarelto$60$25,41016 claims
PfizerEliquis$97$19,65918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,153 acute care providers in California.

Other acute care in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →